Expert opinion on emerging drugs

Keyphrases

Publications

2024

Sophie Köhne, Thomas Hillemacher, Alexander Glahn, Patrick Bach
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. Expert opinion on emerging drugs (2024)
Jack K Tolson, Robert L Menuet, Gianni H Ly, Benjamin A Chanes, Elizabeth A Bryan, Saurabh Kataria, Julian Kim, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review. Expert opinion on emerging drugs (2024)
Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Otani Tomohiro, Takashi Kobayashi, Asako Nogami, Satoru Saito, Nakajima Atsushi
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Expert opinion on emerging drugs (2024)
Francis Proulx-Rocray, Denis Soulières
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma. Expert opinion on emerging drugs (2024)
Divya Kapoor, Pankaj Sharma, Deepak Shukla
Emerging drugs for the treatment of herpetic keratitis. Expert opinion on emerging drugs (2024)
William C Upshaw, Lenise G Soileau, Nicholas R Storey, Kassady A Perkinson, Patrick M Luther, Noah J Spillers, Christopher L Robinson, Cole Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D Kaye
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert opinion on emerging drugs (2024)
William C Upshaw, Lenise G Soileau, Nicholas R Storey, Kassady A Perkinson, Patrick M Luther, Noah J Spillers, Christopher L Robinson, Benjamin C Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D Kaye
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert opinion on emerging drugs (2024)

volume 29, number 1, 2024

Ahmad Shamabadi, Hanie Karimi, Razman Arabzadeh Bahri, Mohsen Motavaselian, Shahin Akhondzadeh
Emerging drugs for the treatment of irritability associated with autism spectrum disorder. Expert opinion on emerging drugs 29 (1) (2024)
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs 29 (1) (2024)
Adi Aran, Dalit Cayam Rand
Cannabinoid treatment for the symptoms of autism spectrum disorder. Expert opinion on emerging drugs 29 (1) (2024)
Inci Yaman, Eric Bouffet
How will tovorafenib change our treatment of pediatric low-grade glioma? Expert opinion on emerging drugs 29 (1) (2024)
Pratheeshaa Nageswaran, Saad Ahmed, Hasan Tahir
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis. Expert opinion on emerging drugs 29 (1) (2024)
Panu Wetwittayakhlang, Talat Bessissow, Peter Laszlo Lakatos
Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials. Expert opinion on emerging drugs 29 (1) (2024)
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs 29 (1) (2024)
Jordan Beveridge, Eileen Kaniecki, Aniketh Naidu, Bret David Silverglate, George Grossberg
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs 29 (1) (2024)
Jordan Beveridge, Eileen Kaniecki, Aniketh Naidu, Bret David Silverglate, George Grossberg
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs 29 (1) (2024)
Ahmad Shamabadi, Hanie Karimi, Razman Arabzadeh Bahri, Mohsen Motavaselian, Shahin Akhondzadeh
Emerging drugs for the treatment of irritability associated with autism spectrum disorder. Expert opinion on emerging drugs 29 (1) (2024)
Jordan Beveridge, Eileen Kaniecki, Aniketh Naidu, Bret David Silverglate, George Grossberg
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs 29 (1) (2024)
Panu Wetwittayakhlang, Talat Bessissow, Peter Laszlo Lakatos
Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials. Expert opinion on emerging drugs 29 (1) (2024)
Pratheeshaa Nageswaran, Saad Ahmed, Hasan Tahir
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis. Expert opinion on emerging drugs 29 (1) (2024)
Adi Aran, Dalit Cayam Rand
Cannabinoid treatment for the symptoms of autism spectrum disorder. Expert opinion on emerging drugs 29 (1) (2024)
Adi Aran, Dalit Cayam Rand
Cannabinoid treatment for the symptoms of autism spectrum disorder. Expert opinion on emerging drugs 29 (1) (2024)
Inci Yaman, Eric Bouffet
How will tovorafenib change our treatment of pediatric low-grade glioma? Expert opinion on emerging drugs 29 (1) (2024)

volume 29, number 2, 2024

Francis Proulx-Rocray, Denis Soulières
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma. Expert opinion on emerging drugs 29 (2) (2024)
William C Upshaw, Lenise G Soileau, Nicholas R Storey, Kassady A Perkinson, Patrick M Luther, Noah J Spillers, Christopher L Robinson, Benjamin C Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D Kaye
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert opinion on emerging drugs 29 (2) (2024)
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies. Expert opinion on emerging drugs 29 (2) (2024)
Divya Kapoor, Pankaj Sharma, Deepak Shukla
Emerging drugs for the treatment of herpetic keratitis. Expert opinion on emerging drugs 29 (2) (2024)
Divya Kapoor, Pankaj Sharma, Deepak Shukla
Emerging drugs for the treatment of herpetic keratitis. Expert opinion on emerging drugs 29 (2) (2024)
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies. Expert opinion on emerging drugs 29 (2) (2024)
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin R J Kolb
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials. Expert opinion on emerging drugs 29 (2) (2024)
Simone Di Cola, Saniya Khan, Lucia Lapenna, Manuela Merli
Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver. Expert opinion on emerging drugs 29 (2) (2024)
Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Tomohiro Otani, Takashi Kobayashi, Asako Nogami, Satoru Saito, Atsushi Nakajima
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Expert opinion on emerging drugs 29 (2) (2024)
William C Upshaw, Lenise G Soileau, Nicholas R Storey, Kassady A Perkinson, Patrick M Luther, Noah J Spillers, Christopher L Robinson, Benjamin C Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D Kaye
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert opinion on emerging drugs 29 (2) (2024)
Simone Di Cola, Saniya Khan, Lucia Lapenna, Manuela Merli
Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver. Expert opinion on emerging drugs 29 (2) (2024)
Simone Di Cola, Saniya Khan, Lucia Lapenna, Manuela Merli
Emerging drugs for the treatment of sarcopenia in cirrhosis of the liver. Expert opinion on emerging drugs 29 (2) (2024)
Divya Kapoor, Pankaj Sharma, Deepak Shukla
Emerging drugs for the treatment of herpetic keratitis. Expert opinion on emerging drugs 29 (2) (2024)
Francis Proulx-Rocray, Denis Soulières
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma. Expert opinion on emerging drugs 29 (2) (2024)
Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Tomohiro Otani, Takashi Kobayashi, Asako Nogami, Satoru Saito, Atsushi Nakajima
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Expert opinion on emerging drugs 29 (2) (2024)
Xiaoyan Li, Richard Bedlack
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis. Expert opinion on emerging drugs 29 (2) (2024)
Jack K Tolson, Robert L Menuet, Gianni H Ly, Benjamin A Chanes, Elizabeth A Bryan, Saurabh Kataria, Julian Kim, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review. Expert opinion on emerging drugs 29 (2) (2024)
Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Tomohiro Otani, Takashi Kobayashi, Asako Nogami, Satoru Saito, Atsushi Nakajima
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis. Expert opinion on emerging drugs 29 (2) (2024)
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin R J Kolb
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials. Expert opinion on emerging drugs 29 (2) (2024)
Xiaoyan Li, Richard Bedlack
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis. Expert opinion on emerging drugs 29 (2) (2024)
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin R J Kolb
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials. Expert opinion on emerging drugs 29 (2) (2024)
Francis Proulx-Rocray, Denis Soulières
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma. Expert opinion on emerging drugs 29 (2) (2024)
Jack K Tolson, Robert L Menuet, Gianni H Ly, Benjamin A Chanes, Elizabeth A Bryan, Saurabh Kataria, Julian Kim, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review. Expert opinion on emerging drugs 29 (2) (2024)
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies. Expert opinion on emerging drugs 29 (2) (2024)
Jack K Tolson, Robert L Menuet, Gianni H Ly, Benjamin A Chanes, Elizabeth A Bryan, Saurabh Kataria, Julian Kim, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review. Expert opinion on emerging drugs 29 (2) (2024)
Xiaoyan Li, Richard Bedlack
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis. Expert opinion on emerging drugs 29 (2) (2024)
William C Upshaw, Lenise G Soileau, Nicholas R Storey, Kassady A Perkinson, Patrick M Luther, Noah J Spillers, Christopher L Robinson, Benjamin C Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D Kaye
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. Expert opinion on emerging drugs 29 (2) (2024)